Latest From Biotech Now

Novartis at India Supreme Court: Evergreening Myths and Patent Reality

Pine

Novartis will go before India’s Supreme Court on September 11, 2012 challenging the refusal by the Indian Patent Office to grant a patent on its cancer drug Glivec.  The Indian Patent Office rejected Novartis’ application under a provision in Indian law which is aimed at guarding against so called “patent evergreening.” BIO has written two posts deconstructing the myth of patent evergreening. 1.  Patent “Ever-Greening”: Novartis Confronts Patent Myth in India 2.  Patent Evergreening in Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , ,

Sequestration Will Be Devastating to the Cure Enterprise

Margaret Anderson

For months, the defense industry has taken the Hill and media outlets by storm detailing the potentially catastrophic impact “sequestration” will have on national security, defense jobs, and our economy. The “S” word stands for automatic spending cuts that will take into effect if Congress does not reach a budget agreement to reduce the deficit by the end of the year. Members of Congress have expressed concern over the potential cuts to defense programs, and even Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , ,

AMP v. Myriad: BIO Statement on Federal Circuit (Re)Decision

courtroom

BIO released the following statement on the Federal Circuit’s decision in the AMP v. Myriad case on remand from the Supreme Court to reconsider in light of Mayo v. Prometheus. “Today’s decision by the U.S. Court of Appeals for the Federal Circuit confirms long-standing law under which valuable DNA preparations, bacterial enzymes, plant-derived antibiotics and other industrially and medically useful substances can be considered for patenting. Such patents have long provided critical incentives for expensive Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , ,

2012 BIO Investor Forum: Looking Ahead to Investment Opportunities

partnering1

The biggest biotech news out of Washington in recent months was the Jumpstart Our Business Startups (JOBS) Act, which passed Congress overwhelmingly and was signed into law by President Obama in April.  For those not familiar, the JOBS Act creates a new category of issuers, called “emerging growth companies” (EGCs), which is defined as newly public companies with than $1 billion in annual revenues and a public float below $700 million. EGCs are given a Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,

MJFF’s Innovative, New Funding Program Addresses the Entire Therapeutic Pipeline

FDOPA-Images

To date, the Michael J. Fox Foundation for Parkinson’s Research has funded over $297 million in research, $77 million of which has been awarded to more than 160 unique, industry-led projects. In June 2012, MJFF announced its newest funding mechanism, the Therapeutic Pipeline Program (TPP), which combines MJFF’s previous Therapeutics Development Initiative (TDI), Repositioning Drugs for PD, and Clinical Intervention Awards (CIA) programs into a single, streamlined funding opportunity.  Open to both industry and academic Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , ,